Navigation Links
CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
Date:1/29/2014

Arlington, Va. CONRAD, a leading reproductive health-research organization based at Eastern Virginia Medical School (EVMS), today announced that they are a winner of the United States Agency for International Development (USAID) Science and Technology Pioneers Prize for their work in developing tenofovir gel. The vaginal gel, containing the antiretroviral tenofovir, was proven to reduce HIV and HSV-2 infections in women in the landmark CAPRISA 004 trial. Offered for the first time this year by the USAID Office of Science and Technology, the prize recognizes excellence in the use of science and technology to solve the latest development challenges.

CONRAD, along with fellow Pioneer Prize winners CAPRISA and FHI 360, worked with support from USAID and the South African government to prove the concept that a vaginal gel containing antiretrovirals used before and after sex could work at the site of infection. The gel was tested on 889 women at two sites in South Africa by Drs. Salim Abdool Karim and Quarraisha Abdool Karim and the successful results were announced at the 2010 International AIDS Society conference in Vienna, Austria in 2010.

CONRAD Scientific and Executive Director Gustavo Doncel, M.D., Ph.D. said, "It is an incredible honor for CONRAD to be one of the recipients of the first ever USAID Pioneers Prize, particularly considering the numerous worthy projects that USAID and PEPFAR support. This was truly a team effort led by brilliant and dedicated researchers at CAPRISA who implemented the trial with the assistance of organizations such as FHI360, Gilead Sciences and CONRAD." Follow on collaborations between CONRAD and CAPRISA resulting from the USAID-funded study continue until the present.

Jeff Spieler, Ph.D. (Hon), MSc, Senior Technical Advisor for Science and Technology in the Office of Population and Reproductive Health at USAID and former CONRAD Executive Director Henry Gabelnick, Ph.D. were early supporters of tenofovir gel and were instrumental in securing the funding to move forward with the trial. "We took a risk," says Dr. Spieler. "Without risk you can't have big wins and taking prudent risks is what science is all about."

A confirmatory study of tenofovir gel called FACTS 001, sponsored by CONRAD and funded by USAID, the South African government and the Bill and Melinda Gates Foundation, is currently ongoing and if the results again show protection, the gel has been fast tracked by the FDA for regulatory approval.

Globally, 35.3 million people are currently infected with HIV, and in South Africa, prevalence of HIV has increased from 10.6% in 2008 to 12.3% in 2012. Young, single women account for the highest rate of new infections, and condom use in South Africa has fallen in all age groups. The need to develop and implement prevention options for those at highest risk of infection continues to be a top public health research priority.

At the close of 2013, CONRAD was awarded up to $80 million over the course of five years from the United States President's Emergency Plan for AIDS Relief (PEPFAR) through USAID. The awards will fund three areas of HIV prevention research including: licensure and implementation of tenofovir gel, development of novel on-demand and longer-acting microbicide leads, and development of objective measures of product adherence for vaginal and rectal microbicides.


'/>"/>

Contact: Annette Larkin
alarkin@conrad.org
703-772-6427
CONRAD
Source:Eurekalert  

Related medicine news :

1. CONRAD to host HIV symposium at 2nd Annual Antivirals Congress
2. Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date
3. USAID awards CONRAD and Eastern Virginia Medical School funding for development of new HIV prevention
4. First anti-tuberculosis medicine under USAID-supported PQM program achieves WHO prequalification
5. URC receives USAIDs Excellence in Mentorship Award
6. USD $1.15 Billion Commitment over Three Years to Help Save the Lives of Children and Women Secured through World Bank, UNICEF, USAID and Norway
7. URC leads new USAID project to improve Haitis health care system
8. IPM receives 2 awards from USAID to advance HIV prevention technologies for women
9. Population Council awarded flagship family planning implementation science project by USAID
10. New USAID cooperative agreement with the Population Council facilitates contraceptive development
11. Population Council awarded USAID cooperative agreement to develop non-antiretroviral HIV microbicide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... Washington, D.C. (PRWEB) , ... June 24, 2016 , ... ... Pro-Am Heroes Golf Classic Tournament held on June 20th at the Woodmont Country ... local charity, Luke’s Wings, an organization dedicated to helping service members that have been ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: